Onko Pharmaceuticals has first taken its place in pharmaceutical sector in 1987 by introducing blood derivative products in Turkey, and by getting distribution on exclusive base from the best known pharmaceutical companies of Europe. Until now Onko keeps on serving in this field by still being the leading importer of blood products through satisfying the high need of blood products in Turkey on a large scale.
In 1995, Kocsel Pharmaceuticals has joined to the family with hepatitis B vaccine and biological product group. In subsequent years, it has undertaken the mission of providing a part of Turkeys vaccine needs, which has occurred due to the attendance of Turkey to the global immunization program. After one year, as a result of success in its own sector; Onko & Kocsel Pharmaceuticals, has achieved to extend its horizon in the pharmaceutical sector by setting up an oncology business unit.
In 2002, Onko & Kocsel Pharmaceuticals took the first step on manufacturing by taking over manufacturing licenses from Roche Pharmaceuticals. This brought a new vision to Onko & Kocsel Pharmaceuticals.
Onko & Kocsel Pharmaceuticals has achieved to reflect its fast success also to its organizational structure and adapted Total Quality System to mantain professional management.
Onko & Kocsel Pharmaceuticals focused on adding new products to its mainly Oncology, Radiation Oncology, Hematology, Neurology, Infection diseases, Urology, Physical Medicine & Rehabilitation, Orthopedics, Rheumatology, Immunology, Dermatology and Internal Medicine portfolio year after year. With its dedicated staff and well organized and positioned structure Onko & Kocsel Pharmaceuticals has reached its target consumers throughout Turkey. In the medical marketing; strong professional customer-focused relations, effective meeting organizations, effective communication skills, power of investment and clinically-focused scientific approaches have constituted its vision. Onko & Kocsel Pharmaceuticals plays a significant role with well-educated, professionally trained, experienced, dynamic and result oriented sale force.
Onko & Kocsel keeps showing promising rise by signing new business agreements with strong companies and expanding its product portfolio in the light of innovative and stable development. Onko & Kocsel Pharmaceuticals looks ahead with confidence with an experience more than 20 years in the Pharmaceutical market.
Contact Details Onko ilaç San. ve Tic. A.Ş.
Koşuyolu Cad. No:34 34718 Koşuyolu Kadıköy – İstanbul / Türkiye
Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over…
As the international community continues its quest to vaccinate the global population against COVID-19, shortages of already approved vaccines have put many countries on the waiting list. Approved vaccines from…
Ümit Dereli is secretary general of the Turkish Association of Research-Based Pharmaceutical Companies (AIFD), which has 35 multinational member companies that together account for almost 50 percent of the Turkish…
When Abdi Ibrahim acquired a 28.5 percent stake in Swiss biotech OM Pharma in September 2020, it represented a historic moment for Turkey’s pharma industry; the first time a Turkish…
There is perhaps no Turkish company in the healthcare sector that is more ambitious than Acıbadem. Not only has the private hospital group revolutionized healthcare in Turkey with its advanced…
Dr Ferhat Farsi, CEO and founding partner of CinnaGen İlaç, shares his experience working for the largest biotech in the MENA region, Turkey’s important role within the global group, and…
Şükran Tümay, a senior partner at executive search and assessment firm Stanton Chase in Turkey, highlights the evolving profiles she looks for when hiring country managers for healthcare and the…
Turkey – home to an 80 million-strong population, a substantial pharmaceuticals market and a universal healthcare system that is the envy of its neighbours – stands as one of the…
Bucking a global trend for increased focus on outpatient and preventative care, Turkey is doubling down on hospital investment. Throughout many of the healthcare systems in North America and Europe, there…
Armağan Vurdu, general secretary of the Istanbul Minerals and Metals Exporters Association (IMMIB) highlights the strategic importance of the chemical and pharmaceutical sectors in Turkey’s exports. He underscores pharma’s role…
Ozlem Fidanci, CEO of the Middle East and Turkey at Philips, shares the collaborative approach Philips has implemented in Turkey and its successes, provides insights into future collaborations and discusses…
Yelda Ulu Colin, general manager of GE Healthcare in Turkey, offers her insider take on the country’s city hospitals project, highlighting the strengths of the Turkish PPP model and ultimately…
Seizing the cost competitiveness of the Turkish market and the government’s nurturing of local manufacturing, Turkish companies are looking to harness their geographic positioning and export to developed and developing…